Guy Shinar

HIL Medical is an R&D-stage medical-technology startup, on an accelerated growth path. We are developing a new class of compact, high-performance cancer proton-therapy systems. HIL applies a patented particle acceleration and beam delivery approach, combining nano-technology with Nobel-Prize-winning ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. Affordable single-room systems are key to widespread adoption of this important therapy, and an enabler of a $10BB market (US). HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. We are headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).

EarlySense is the global leader in contact-free, continuous monitoring solutions for the healthcare continuum. EarlySense empowers clinicians to provide proactive patient care by supporting clinical teams detect opportunities for intervention.

Dune Medical Devices was founded in 2002 to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the ability to detect cancer in real time, this technology holds promise for a broad range of diagnostic and therapeutic applications.

HIL Medical is an R&D-stage medical-technology startup, on an accelerated growth path. We are developing a new class of compact, high-performance cancer proton-therapy systems. HIL applies a patented particle acceleration and beam delivery approach, combining nano-technology with Nobel-Prize-winning ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. Affordable single-room systems are key to widespread adoption of this important therapy, and an enabler of a $10BB market (US). HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. We are headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).

The Weizmann Institute of Science is one of the world’s leading multidisciplinary research institutions. The Institute has five faculties – Mathematics and Computer Science, Physics, Chemistry, Biochemistry and Biology – and the faculties in turn are divided into 17 scientific departments. Over the years, work by Institute scientists has widely expanded our knowledge in these areas, created new research fields, and combined traditional scientific disciplines in multidisciplinary studies that steer research into new, exciting and often surprising paths. In addition, the Weizmann School of Science, the Institute’s university arm, trains research students pursuing graduate degrees. Over the years, the Weizmann Institute has grown with the country, and it has been the site of numerous milestones in Israel’s science. Institute scientists were pioneers in the field of cancer research in Israel. Others planned and built the country’s first electronic computer, one of the first in the world; yet others founded the first nuclear physics department and erected a particle accelerator next door. They were the first to establish a company for transferring knowledge from academia to industry (YEDA Research and Development), and they initiated the founding of a science-based industrial park near the Institute.

EarlySense is the global leader in contact-free, continuous monitoring solutions for the healthcare continuum. EarlySense empowers clinicians to provide proactive patient care by supporting clinical teams detect opportunities for intervention.